ISSN: 2008-2258
Vol 10 (2017): Supplement 1 -Winter
Evaluation of IL-17B and IL-17F mRNA expression in peripheral blood mononuclear cells and association with clinical outcome of IBD patients
Gastroenterology and Hepatology from Bed to Bench,
,
,
Page S79-S84
https://doi.org/10.22037/ghfbb.v0i0.1272
Abstract
Aim: In this study, we determined the gene expression analysis of IL-17 gene family for early detection of subclinical inflammation among IBD patients.
Background: Cytokines have a vital role in the pathogenesis of inflammatory bowel disease (IBD). Interleukin-17 is the signature cytokine of the recently identified T helper 17 (Th17) cell subset. IL-17F is mainly involved in mucosal host defense mechanisms whereas the functions of IL-17B remain largely elusive.
Methods: In this cross-sectional study, IBD patients divided into two active and inactive groups. Peripheral blood mononuclear cells (PBMCs) from 38 IBD patients which 20 inactive samples and 18 active individuals were collected. Changes of IL-17 F and IL-17B mRNA expression level evaluated by quantitative-real time-PCR.
Results: mRNA expression level of IL-17B and IL-17F in CD, UC, active and inactive groups have been assessed and there were no significant differences (P>0.05). Patients were classified into five different categories as follows: i) 5?ASA; ii) 5?ASA + Pred; iii) 5?ASA + AZA; iv) 5?ASA + Pred + AZA; v) 5?ASA + Pred + AZA + IFX according to medication usage, expression of IL-17F and IL-17B had no differences (p>0.05).
Conclusion: Evaluation of IL-17B and IL-17F mRNA expression level illustrate no difference among active and inactive patients. Therefore, IL-17B and IL-17F are not biomarkers in an Iranian IBD patients.
- Inflammatory Bowel Disease
- Crohn’s Disease
- Ulcerative Colitis
- Interleukin-17
- qPCR
How to Cite
References
Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World journal of gastroenterology: WJG. 2006;12(38):6102.
Norouzinia M, Chaleshi V, Alizadeh AHM, Zali MR. Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment. Gastroenterol Hepatol Bed Bench. 2017;10(3):155-67.
Bianco AM, Girardelli M, Tommasini A. Genetics of inflammatory bowel disease from multifactorial to monogenic forms. World journal of gastroenterology. 2015;21(43):12296.
Malik TA. Inflammatory Bowel Disease. Surgical Clinics. 2015;95(6):1105-22.
Balaii H, Aghdaei HA, Farnood A, Habibi M, Mafi AA, Firouzi F, et al. Time trend analysis and demographic features of inflammatory bowel disease in Tehran. Gastroenterology and Hepatology from bed to bench. 2015;8(4):253.
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nature reviews Gastroenterology & hepatology. 2015;12(12):720-7.
McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology. 2015;149(5):1163-76. e2.
Nourian M, Chaleshi V, Pishkar L, Azimzadeh P, Baradaran Ghavami S, Balaii H, et al. Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. Biomedical Reports. 2017;6(6):698-702.
Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. nature. 2012;491(7422):119.
Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Human genomics. 2010;5(1):30.
Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65-70.
Middel P, Reich K, Polzien F, Blaschke V, Hemmerlein B, Herms J, et al. Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease. Gut. 2001;49(6):795-803.
Rouvier E, Luciani M, Mattei M, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. The Journal of Immunology. 1993;150(12):5445-56.
Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochemical and biophysical research communications. 2011;407(2):348-54.
Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, et al. A protective role by interleukin-17F in colon tumorigenesis. PloS one. 2012;7(4):e34959.
Friedrich M, Diegelmann J, Schauber J, Auernhammer C, Brand S. Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease. Mucosal immunology. 2015;8(4):943-58.
Hölttä V, Klemetti P, Sipponen T, Westerholm‐Ormio M, Kociubinski G, Salo H, et al. IL‐23/IL‐17 immunity as a hallmark of Crohn's disease. Inflammatory bowel diseases. 2008;14(9):1175-84.
Nielsen O, Kirman I, Rüdiger N, Hendel J, Vainer B. Upregulation of interleukin-12 and-17 in active inflammatory bowel disease. Scandinavian journal of gastroenterology. 2003;38(2):180-5.
Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, et al. Role of the novel Th17 cytokine IL‐17F in inflammatory bowel disease (IBD): upregulated colonic IL‐17F expression in active Crohn's disease and analysis of the IL17F p. His161Arg polymorphism in IBD. Inflammatory bowel diseases. 2008;14(4):437-45.
- Abstract Viewed: 249 times
- PDF Downloaded: 90 times
